SCHEMBL10131378

SCHEMBL10131378

Bc1ccc2c(C)n[nH]c2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 2/20 0.46
ADORA2B P29275 2/20 0.46
CYP1A2 P05177 1/20 0.39
PDPK1 O15530 7/20 0.36
JAK2 O60674 3/20 0.36
ITK Q08881 2/20 0.36
HSP90AB1 P08238 1/20 0.34
AURKA O14965 1/20 0.34
TGFBR1 P36897 1/20 0.34
ROCK1 Q13464 1/20 0.34
AURKB Q96GD4 1/20 0.34
FGFR1 P11362 1/20 0.33
FGFR2 P21802 1/20 0.33
FGFR3 P22607 1/20 0.33
SGK1 O00141 1/20 0.33
MAP2K4 P45985 1/20 0.33
ESR1 P03372 1/20 0.33
DYRK1A Q13627 1/20 0.32
JAK1 P23458 1/20 0.31
TYK2 P29597 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9909085 0.84 ADORA2A (0.46) ADORA2AADORA2BCYP1A2PDPK1JAK2
SCHEMBL31552439 0.79 ITK (0.53) ADORA2AADORA2BCYP1A2ITKMAP2K4
SCHEMBL12247 0.79 ITK (0.53) ADORA2AADORA2BCYP1A2ITKMAP2K4
SCHEMBL12292289 0.78 PDPK1 (0.60) PDPK1JAK2AURKATGFBR1ROCK1
SCHEMBL8212257 0.76 MAP2K4 (0.56) ADORA2AADORA2BITKMAP2K4CDK1
SCHEMBL11034 0.76 PDPK1 (0.63) ADORA2AADORA2BCYP1A2PDPK1JAK2
SCHEMBL588513 0.76 AXL (0.50) ADORA2AADORA2BCYP1A2PDPK1JAK2
SCHEMBL21937470 0.76 ADORA2A (0.46) ADORA2AADORA2BCYP1A2PDPK1JAK2
SCHEMBL176952 0.76 PDPK1 (0.59) ADORA2AADORA2BCYP1A2PDPK1JAK2
SCHEMBL3155790 0.76 CHEK1 (0.50) ADORA2AADORA2BCYP1A2MAP2K4DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120010181-A1 COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS MERCK SHARP & DOHME CORP. 2012-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010181-A1 COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS TNF, ADAMTS1, ADAMTS7 ADORA2A 3925/4885ADORA2B 2755/4885CYP1A2 1067/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.